Literature DB >> 24045449

Outpatient endovascular aortic aneurysm repair: experience in 100 consecutive patients.

Mario Louis Lachat1, Felice Pecoraro, Dieter Mayer, Carole Guillet, Michael Glenck, Zoran Rancic, Christian Alexander Schmidt, Gilbert Puippe, Frank Junior Veith, Jacques Bleyn, Dominique Bettex.   

Abstract

OBJECTIVES: To present the safety, feasibility, costs, and patient satisfaction of outpatient endovascular aneurysm repair (EVAR).
BACKGROUND: Our experience in more than 1000 patients indicated that in technically uncomplicated EVAR procedures, the only need for hospitalization was for access vessel complications (bleeding or occlusion) requiring secondary procedures. These complications could always be identified within the first 3 hours after EVAR.
METHODS: Two-center retrospective analysis of prospectively gathered data on 100 consecutive elective outpatient EVAR cases (Outpt EVAR). Inclusion criteria for Outpt EVAR were as follows: asymptomatic clinical state, informed consent, travel time to the hospital if readmission was required of less than 60 minutes, adult observer assistance for the first 24 hours, and a technically uncomplicated EVAR procedure. EVAR was mostly performed under local anesthesia and with percutaneous access. Patients were discharged home after 4 to 6 hours of observation and checked the next morning and on the fifth postoperative day in the outpatient clinic.
RESULTS: From 104 patients selected, 4 (3.8%) preferred primary hospitalization and were excluded from further analysis. Four patients (4%) with access vessel complications required additional procedures and had to be hospitalized overnight. The 30-day readmission rate was 4% (4), all due to access vessel stenosis (2) or false aneurysm (2). There was no 30-day mortality. From the 96 outpatients who completed Outpt EVAR, 93 (97%) would undergo Outpt EVAR again and would recommend it to others. Cost comparison showed in 42 matched contemporary patients treated with just a standard stent graft that costs were significantly lower in 21 Outpt EVAR patients than in 21 inpatient EVAR.
CONCLUSIONS: Elective Outpt EVAR can be performed safely, provided certain criteria are fulfilled and specific precautions are taken. In this series, Outpt EVAR morbidity was minimal, especially delirium common in elderly patients recovering from inpatient vascular surgery and nosocomial infections did not occur. Finally, patient satisfaction was high and costs were less than with standard inpatient EVAR.

Entities:  

Mesh:

Year:  2013        PMID: 24045449     DOI: 10.1097/SLA.0b013e3182a617f1

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

1.  Mortality rates and risk factors for emergent open repair of abdominal aortic aneurysms in the endovascular era.

Authors:  Felice Pecoraro; Steffen Gloekler; Caecilia E Mader; Malgorzata Roos; Lyubov Chaykovska; Frank J Veith; Neal S Cayne; Nicola Mangialardi; Thomas Neff; Mario Lachat
Journal:  Updates Surg       Date:  2017-09-14

2.  Functional status predicts major complications and death after endovascular repair of abdominal aortic aneurysms.

Authors:  Donald G Harris; Ilynn Bulatao; Connor P Oates; Richa Kalsi; Charles B Drucker; Nandakumar Menon; Tanya R Flohr; Robert S Crawford
Journal:  J Vasc Surg       Date:  2017-03-01       Impact factor: 4.268

3.  Episode-based cost reduction for endovascular aneurysm repair.

Authors:  Nathan K Itoga; Ning Tang; Diana Patterson; Rika Ohkuma; Raymond Lew; Matthew W Mell; Ronald L Dalman
Journal:  J Vasc Surg       Date:  2018-06-28       Impact factor: 4.268

4.  Deep Learning and Multivariable Models Select EVAR Patients for Short-Stay Discharge.

Authors:  Devin S Zarkowsky; Besma Nejim; Itay Hubara; Caitlin W Hicks; Philip P Goodney; Mahmoud B Malas
Journal:  Vasc Endovascular Surg       Date:  2020-09-10       Impact factor: 1.089

5.  Comparison of perioperative costs with fast-track vs standard endovascular aneurysm repair.

Authors:  Zvonimir Krajcer; Venkatesh G Ramaiah; Esteban A Henao; Wayne K Nelson; Mohammed M Moursi; Hiranya A Rajasinghe; Louise H Anderson; Larry E Miller
Journal:  Vasc Health Risk Manag       Date:  2019-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.